TürkiyeHealth policy
Domestic nusinersen development: mass production targeted for first half of 2026
Based on a single news source or an institutional announcement. The level of scientific evidence is low; check the details with a doctor.
Health Minister Kemal Memişoğlu announced that the synthesis of the active ingredient nusinersen has been completed. The synthesis was carried out at an R&D center opened in Tekirdağ. Nusinersen is used in the treatment of SMA. It was stated that clinical study and licensing processes are ongoing. Mass production is targeted for the first half of 2026. The drug is currently imported and covered by SGK (Social Security Institution).
What does it mean for patients and families?
There is no change to current treatment. Until the domestic product is licensed, patients continue their treatment as before.
Source
The source page was opened and read on October 7, 2026. Summary prepared by the Doktorclub editorial team and translated from Turkish; it has not yet been reviewed by a physician (a scientific board is being set up).
This page is translated from the Turkish original.
Related disease: Spinal muscular atrophy (SMA)
This page reports a development; it is not a treatment recommendation. Your doctor decides whether a treatment is right for you.